GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Beneish M-Score

ENCell Co (XKRX:456070) Beneish M-Score : -3.02 (As of Dec. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is ENCell Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.02 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for ENCell Co's Beneish M-Score or its related term are showing as below:

XKRX:456070' s Beneish M-Score Range Over the Past 10 Years
Min: -4.26   Med: -3.64   Max: -3.02
Current: -3.02

During the past 4 years, the highest Beneish M-Score of ENCell Co was -3.02. The lowest was -4.26. And the median was -3.64.


ENCell Co Beneish M-Score Historical Data

The historical data trend for ENCell Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENCell Co Beneish M-Score Chart

ENCell Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -4.26 -3.02

ENCell Co Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Beneish M-Score - - -4.26 -3.02

Competitive Comparison of ENCell Co's Beneish M-Score

For the Biotechnology subindustry, ENCell Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENCell Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ENCell Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ENCell Co's Beneish M-Score falls into.



ENCell Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ENCell Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3255+0.528 * -2.6673+0.404 * 1.6804+0.892 * 1.4287+0.115 * 0.6704
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7873+4.679 * 0.031531-0.327 * 0.0927
=-3.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was ₩2,318 Mil.
Revenue was ₩10,526 Mil.
Gross Profit was ₩-358 Mil.
Total Current Assets was ₩22,928 Mil.
Total Assets was ₩43,981 Mil.
Property, Plant and Equipment(Net PPE) was ₩20,029 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩4,239 Mil.
Selling, General, & Admin. Expense(SGA) was ₩1,207 Mil.
Total Current Liabilities was ₩2,742 Mil.
Long-Term Debt & Capital Lease Obligation was ₩3,097 Mil.
Net Income was ₩-5,054 Mil.
Gross Profit was ₩0 Mil.
Cash Flow from Operations was ₩-6,440 Mil.
Total Receivables was ₩1,224 Mil.
Revenue was ₩7,367 Mil.
Gross Profit was ₩668 Mil.
Total Current Assets was ₩31,644 Mil.
Total Assets was ₩54,746 Mil.
Property, Plant and Equipment(Net PPE) was ₩22,343 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩2,964 Mil.
Selling, General, & Admin. Expense(SGA) was ₩1,073 Mil.
Total Current Liabilities was ₩74,430 Mil.
Long-Term Debt & Capital Lease Obligation was ₩3,978 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2317.868 / 10525.887) / (1223.915 / 7367.362)
=0.220206 / 0.166127
=1.3255

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(667.535 / 7367.362) / (-357.563 / 10525.887)
=0.090607 / -0.03397
=-2.6673

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (22928.326 + 20028.85) / 43981.151) / (1 - (31644.291 + 22343.474) / 54746.297)
=0.023282 / 0.013855
=1.6804

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=10525.887 / 7367.362
=1.4287

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2963.816 / (2963.816 + 22343.474)) / (4239.098 / (4239.098 + 20028.85))
=0.117113 / 0.174679
=0.6704

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1207.376 / 10525.887) / (1073.335 / 7367.362)
=0.114705 / 0.145688
=0.7873

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3097.371 + 2742.451) / 43981.151) / ((3977.802 + 74430.247) / 54746.297)
=0.13278 / 1.432207
=0.0927

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5053.52 - 0 - -6440.273) / 43981.151
=0.031531

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ENCell Co has a M-score of -3.02 suggests that the company is unlikely to be a manipulator.


ENCell Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ENCell Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ENCell Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
701 Yeongdong-daero, 11th floor, Gangnam-gu, Seoul, KOR
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.

ENCell Co Headlines

No Headlines